Revised IPSS-R (myelodysplastic syndromes)
Revised IPSS-R (myelodysplastic syndromes) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the Revised IPSS-R (myelodysplastic syndromes) → Runs in your browser. No signup, no tracking.
What this is
Revised IPSS-R (myelodysplastic syndromes) is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. Revised IPSS-R (myelodysplastic syndromes) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. Read the source ↗
Worked example: IPSS-R 4: Intermediate risk; median overall survival 3.0 years, time to 25% AML evolution 3.2 years (Greenberg 2012).
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.